Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SAB BiotherapeuticsSABS -0.79%30 EV-to-OCF is -4.54 as of Aug. 12, 2026. GuruFocus rates SABS with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 1,406 Biotechnology companies, SAB Biotherapeutics ranks better than 55.41% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, SAB Biotherapeutics's Enterprise Value is $244.61 Mil.
SAB Biotherapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-53.94 Mil. Therefore, SAB Biotherapeutics's EV-to-OCF for today is -4.54.
The historical rank and industry rank for SAB Biotherapeutics's EV-to-OCF or its related term are showing as below:
SABS'
s EV-to-OCF Range Over the Past 10 Years
Min: -4.59 Med: 0 Max: -4.4
Current: -4.54
During the past 7 years, the highest EV-to-OCF of SAB Biotherapeutics was -4.40. The lowest was -4.59. And the median was .
SABS's EV-to-OCF is ranked better than 55.41% of 1406
companies
in the Biotechnology industry
Industry Median: -3.515
vs SABS: -4.54
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
SAB Biotherapeutics (NAS:SABS) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
SAB Biotherapeutics's PE Ratio (TTM) for today is calculated as:
SAB Biotherapeutics's share price for today is $3.76.
SAB Biotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.496.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
SAB Biotherapeutics EV-to-OCF Related Terms
SAB Biotherapeutics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for SAB Biotherapeutics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, SAB Biotherapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SAB Biotherapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SAB Biotherapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where SAB Biotherapeutics's EV-to-OCF falls into.
SAB Biotherapeutics's current Enterprise Value is $244.61 Mil.
SAB Biotherapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-53.94 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SAB Biotherapeutics (SABS) has a EV-to-OCF of -4.54 as of Aug. 12, 2026. According to the industry distribution chart, SAB Biotherapeutics ranks #627 out of 1406 companies in the Biotechnology industry, placing it in the top 44.6%.
Is SAB Biotherapeutics' EV-to-OCF too high?
SAB Biotherapeutics' current EV-to-OCF is -4.54. Based on the distribution chart, SAB Biotherapeutics ranks #627 out of 1406 companies in the Biotechnology industry, which is above the industry midpoint. Overall, SAB Biotherapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does SAB Biotherapeutics' EV-to-OCF compare to SLGL and BCYC?
According to the Biotechnology industry distribution chart, SAB Biotherapeutics ranks #627 out of 1406 companies for EV-to-OCF. This puts SAB Biotherapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. SAB Biotherapeutics's current EV-to-OCF is -4.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SAB Biotherapeutics stock overvalued right now?
SAB Biotherapeutics (SABS) has a current EV-to-OCF of -4.54. The current EV-to-OCF is -4.54. SAB Biotherapeutics' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For SAB Biotherapeutics (SABS), the current EV-to-OCF is -4.54 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
30GF Score
Get the complete analysis for SABS
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SABS has been successfully added to your 
